Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 30, 2026, the Board of Directors (“Board”) of Omnicell, Inc. (“Omnicell” or the “Company”) appointed Mr. Nnamdi Njoku to serve as President of the Company, effective July 1, 2026. Mr. Njoku will retain his role of Chief Operating Officer of the Company.…
Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric pharmacy and nursing solutions for all settings of care. As an intelligent medication management technology company, Omnicell empowers autonomous medication management by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that improve efficiency and enhance patient safety for healthcare facilities worldwide. Learn more at omnicell.com.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 30, 2026, the
Board of Directors (“Board”) of Omnicell, Inc. (“Omnicell” or the “Company”) appointed Mr. Nnamdi
Njoku to serve as President of the Company, effective July 1, 2026. Mr. Njoku will retain his role of Chief Operating Officer
of the Company. A press release announcing the appointment and promotion of Mr. Njoku as President of the Company is attached as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
In his role as President and
Chief Operating Officer, Mr. Njoku will shape and advance Omnicell’s long-term growth strategy and innovation roadmap, focused on scaling global operations while seeking
to ensure seamless operational execution and excellence across product, innovation, and customer experience. In
connection with Mr. Njoku’s promotion, the Company’s President, Chief Executive Officer and Chairman of the Board, Randall
A. Lipps, stepped down from his role as President of the Company. Mr. Lipps will continue to serve as Chief Executive Officer and
Chairman of the Board, and there will be no compensation changes in connection with Mr. Lipps’ transitioning President duties
to Mr. Njoku. Mr. Njoku will continue to report to Mr. Lipps.
Before being appointed as
President and Chief Operating Officer of Omnicell, Mr. Njoku, age 49, served as Executive Vice President and Chief Operating Officer
of the Company from October 2024 until June 2026. Prior to joining Omnicell, Mr. Njoku served as President - Sports
Medicine, Surgical, Upper Extremities and Restorative Therapies of Zimmer Biomet Holdings, Inc., a global medical technology leader,
from March 2023 to September 2024. From April 2022 to March 2023, Mr. Njoku served as Senior Vice President &
President - Neuromodulation at Medtronic, Inc., a subsidiary of Medtronic plc, a leading global healthcare technology company
(“Medtronic”). Prior to that, he served as President - Mechanical Circulatory Support from August 2019 to March 2022,
as Vice President & General Manager - Transformative Solutions from February 2018 to August 2019 and as Vice
President, Surgical Synergy from September 2017 to October 2018 at Medtronic. From August 2005 to August 2017, Mr. Njoku
held executive operational roles of increasing responsibility at Medtronic. Prior to Medtronic, Mr. Njoku served in operational roles
of increasing responsibility at UnitedHealth Group and Deloitte Consulting. Mr. Njoku received a Bachelor of Arts degree in business
administration from the University of St. Thomas and an MBA from Cornell University.
There are no arrangements
or understandings between Mr. Njoku and any other persons pursuant to which he was appointed as President. There are no family relationships
between Mr. Njoku and any director or executive officer of the Company, and Mr. Njoku has no direct or indirect material interest
in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
In connection with his appointment
and promotion to President and Chief Operating Officer, the Compensation Committee of the Board approved a one-time equity award, subject
to the terms and conditions of the Company's 2009 Equity Incentive Plan and applicable award agreement, for Mr. Njoku with a target
grant date value of approximately $500,000 in the form of restricted stock units, one-third (1/3) of which will vest following the one-year
anniversary of the grant date and the remaining two-thirds (2/3) will vest in equal amounts on the two- and three-year anniversaries of
the grant date, respectively. In his role as President and Chief Operating Officer of the Company, Mr. Njoku’s annual base
salary for 2026 is unchanged and remains $661,000 per annum and his target cash bonus for 2026 remains 100% of his annual base salary.
Mr. Njoku will remain
eligible to participate in the Company’s Executive Bonus Plan, Executive Severance Plan and other compensation and benefit arrangements
applicable to similarly situated executive officers, including certain perquisites and indemnification protections. Descriptions of the
material terms of such arrangements are incorporated herein by reference to the Company’s Definitive Proxy Statement on Schedule
14A filed with the Securities and Exchange Commission on April 13, 2026 (the “Definitive Proxy Statement”), as may be
applicable. The foregoing descriptions are qualified in their entirety by reference to the Definitive Proxy Statement.
Filed exhibits (1)
EX-99.1 (by filename) tm2619353d1_ex99-1.htm
EX-99.1
2
tm2619353d1_ex99-1.htm
EXHIBIT 99.1
Exhibit 99.1
Contact:
Betsy Martinelli
Director, Corporate Marketing
betsy.martinelli@omnicell.com
Nnamdi Njoku Appointed President of Omnicell
Njoku continues to lead global operations and
advance Omnicell's innovation and AI platform strategy; Randall Lipps continues to serve as Chief Executive Officer and Chairman of the
Board
Fort Worth, Texas - July 1,
2026 - Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell” or the “Company”), a leading healthcare
technology provider focused on empowering autonomous medication management, today announced that Nnamdi Njoku has been appointed President
of the Company, effective July 1, 2026. Mr. Njoku will retain his role of Chief Operating Officer (COO), while Randall Lipps
will continue to serve as Chief Executive Officer and Chairman of the Board, with a continued focus on strategic collaborations and the
long-term evolution of Omnicell's solution portfolio.
As President and COO, Mr. Njoku will shape and advance Omnicell’s
long-term growth strategy and innovation roadmap, focused on scaling global operations while seeking to ensure seamless operational execution
and excellence across product, i…